DeepkinetiX utilizes AI-powered digital twins and patient data to enhance drug development by providing precise pharmacokinetic and pharmacodynamic modeling. This approach reduces research and development costs and timelines while improving the accuracy of dosing recommendations and minimizing the reliance on animal testing.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development processes rely heavily on animal testing and lack precise pharmacokinetic (PK) and pharmacodynamic (PD) modeling, leading to high research and development costs, extended timelines, and inaccurate dosing recommendations. The inability to effectively model drug behavior in humans early in the development cycle results in late-stage failures and increased reliance on animal models with limited translational relevance.
Solution
DeepkinetiX offers KinetixFlow™, an AI-powered SaaS platform that leverages digital twins and patient-derived ex vivo data to optimize drug development through model-informed drug development (MIDD). The platform provides precise PK/PD, physiologically based pharmacokinetic (PBPK), and quantitative systems pharmacology (QSP) modeling to simulate drug behavior, predict efficacy and safety, and refine dosing strategies. By incorporating data from 2D cell lines or 3D organoids/spheroids, KinetixFlow™ generates AI-driven insights that accelerate R&D, reduce costs, and expedite the path to market. The platform enables researchers to validate drug targets, screen compounds, and optimize leads with greater accuracy and efficiency, minimizing the need for animal testing.
Target Audience
The primary target audience includes pharmaceutical companies, hospitals, CROs, drug development companies, and biotech startups involved in drug discovery and development.
Features
- AI-driven PK/PD, PBPK, and QSP modeling for comprehensive drug behavior simulation
- Integration of patient-derived ex vivo data, including 2D cell lines and 3D organoids/spheroids
- Customizable platform tailored to specific drug development goals and challenges
- AI-driven insights for target validation, compound screening, and lead optimization
- Precise dosing recommendations based on individual patient profiles and immune/gene/cytokine expression